[go: up one dir, main page]

ECSP13013036A - Alfa glucosidasa ácida modificada con procesamiento acelerado - Google Patents

Alfa glucosidasa ácida modificada con procesamiento acelerado

Info

Publication number
ECSP13013036A
ECSP13013036A ECSP13013036A ECSP13013036A EC SP13013036 A ECSP13013036 A EC SP13013036A EC SP13013036 A ECSP13013036 A EC SP13013036A EC SP13013036 A ECSP13013036 A EC SP13013036A
Authority
EC
Ecuador
Prior art keywords
accelerated processing
modified acid
alfa
glucosidase modified
alfa glucosidase
Prior art date
Application number
Other languages
English (en)
Inventor
William M Canfield
Rodney J Moreland
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13013036(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of ECSP13013036A publication Critical patent/ECSP13013036A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporciona un polipéptido de alfa-glucosidasa ácida humana modificada, así como métodos para producir y usar la alfa-glucosidasa ácida humana modificada para tratar una glucogenosis.
ECSP13013036 2011-04-22 2013-11-21 Alfa glucosidasa ácida modificada con procesamiento acelerado ECSP13013036A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161478336P 2011-04-22 2011-04-22

Publications (1)

Publication Number Publication Date
ECSP13013036A true ECSP13013036A (es) 2015-04-30

Family

ID=46000406

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013036 ECSP13013036A (es) 2011-04-22 2013-11-21 Alfa glucosidasa ácida modificada con procesamiento acelerado

Country Status (24)

Country Link
US (1) US20140186326A1 (es)
EP (1) EP2699676A1 (es)
JP (2) JP2014513952A (es)
KR (1) KR20140037082A (es)
CN (1) CN103797115A (es)
AU (1) AU2012245280A1 (es)
BR (1) BR112013026976A2 (es)
CA (1) CA2833371A1 (es)
CL (1) CL2013003010A1 (es)
CO (1) CO6811810A2 (es)
CR (1) CR20130555A (es)
EC (1) ECSP13013036A (es)
GT (1) GT201300252A (es)
IL (1) IL228871A0 (es)
MA (1) MA35125B1 (es)
MX (1) MX2013012345A (es)
NI (1) NI201300110A (es)
PE (1) PE20140617A1 (es)
PH (1) PH12013502149A1 (es)
RU (1) RU2013151875A (es)
SG (2) SG10201605874TA (es)
TN (1) TN2013000427A1 (es)
WO (1) WO2012145644A1 (es)
ZA (1) ZA201307696B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2901978A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
ES2967620T3 (es) 2014-09-30 2024-05-03 Amicus Therapeutics Inc Alfa-glucosidasa ácida altamente potente con carbohidratos potenciados
CA3003750A1 (en) * 2015-11-06 2017-05-11 Biomarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
KR102510941B1 (ko) * 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
IL319770A (en) * 2016-03-30 2025-05-01 Amicus Therapeutics Inc Method for selecting recombinant proteins with high mannose-6-phosphate content
KR102758570B1 (ko) 2016-03-30 2025-01-23 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
SG11201901494UA (en) 2016-09-12 2019-03-28 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3624831B1 (en) 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
KR101942093B1 (ko) * 2018-01-05 2019-01-24 인하대학교 산학협력단 만노시다제 억제제를 포함하는 고만노즈 타입 n-당쇄를 갖는 인간 리소좀 효소 생산용 조성물
US12258597B2 (en) 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
WO2019222663A1 (en) 2018-05-17 2019-11-21 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
US20220331408A1 (en) 2019-07-09 2022-10-20 Genethon Treatment of glycogen storage disease (gsd)
CA3159018A1 (en) * 2019-11-19 2021-05-27 Michael W. O'CALLAGHAN Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
CA2305768A1 (en) 1997-10-29 2000-02-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
ATE410506T1 (de) 1998-12-07 2008-10-15 Genzyme Corp Behandlung der pompeschen krankheit
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
BR122015016313B8 (pt) 2001-07-16 2021-05-25 Genzyme Corp composto semelhante à ceramida e método de preparar um composto
US6835831B2 (en) 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
PT1587923E (pt) * 2003-01-22 2011-12-07 Univ Duke Construções melhoradas para a expressão de polipéptidos lisossomais
US20100196345A1 (en) 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
EP3346010A1 (en) 2003-06-24 2018-07-11 Genzyme Corporation Novel beta-actin and rps21 promoters and uses thereof
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
JP2010509344A (ja) * 2006-11-13 2010-03-25 ザイストール セラピューティクス， インコーポレイテッド ポンペ病を治療するための方法
ES2735023T3 (es) 2008-12-16 2019-12-13 Genzyme Corp Intermedios sintéticos para preparar conjugados de oligosacáridos-proteínas
WO2010096369A1 (en) * 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof

Also Published As

Publication number Publication date
CR20130555A (es) 2013-12-09
PH12013502149A1 (en) 2019-09-02
RU2013151875A (ru) 2015-05-27
CA2833371A1 (en) 2012-10-26
MX2013012345A (es) 2015-05-07
CN103797115A (zh) 2014-05-14
WO2012145644A1 (en) 2012-10-26
CL2013003010A1 (es) 2014-03-07
AU2012245280A1 (en) 2013-11-07
SG10201605874TA (en) 2016-09-29
JP2017035091A (ja) 2017-02-16
PE20140617A1 (es) 2014-05-28
KR20140037082A (ko) 2014-03-26
EP2699676A1 (en) 2014-02-26
ZA201307696B (en) 2014-07-30
SG194486A1 (en) 2013-12-30
MA35125B1 (fr) 2014-05-02
GT201300252A (es) 2015-02-09
JP2014513952A (ja) 2014-06-19
NI201300110A (es) 2014-02-28
TN2013000427A1 (en) 2015-03-30
US20140186326A1 (en) 2014-07-03
CO6811810A2 (es) 2013-12-16
BR112013026976A2 (pt) 2019-09-24
IL228871A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
ECSP13013036A (es) Alfa glucosidasa ácida modificada con procesamiento acelerado
BR112013032229A2 (pt) método de tratamento hidrocatalítico hidrotérmico de biomassa, e, composição
UY34577A (es) Método para estabilizar fibra de lignina y su posterior conversión en fibra de carbono
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
HUE039816T2 (hu) Lignocellulózos biomassza egylépcsõs autohidrolízis és C5 kikerülésével történõ enzimatikus hidrolízis és poszthidrolízis alkalmazásával történõ feldolgozásának eljárásai
BR112015009042A2 (pt) populações de célula renal e usos das mesmas
EA201690718A1 (ru) Способ обработки целлюлозосодержащей биомассы
UA110813C2 (uk) Лікування ліподистрофії
MX375786B (es) Biosintesis microbiana de ergotioneina.
MX2013010557A (es) Anticuerpo del factor tisular humano y usos de este.
PL2865038T3 (pl) Elektroda dwubiegunowa i sposób jej wytwarzania
BR112015008111A2 (pt) célula de levedura geneticamente modificada, e , método para a produção de 3hp.
AR085793A1 (es) Metodo para producir una fibra de lignina
MX2016003737A (es) Microorganismo recombinante para la mejora de produccion de productos quimicos finos.
MX377149B (es) Microorganismo recombinante para la produccion mejorada de productos quimicos finos.
AR093986A1 (es) Cuerpos de carbono ferromagneticos y proceso de produccion
UY33992A (es) Métodos para modificar la biosintesis de la lignina y mejorar la digestibilidad
MX2016002651A (es) Microorganismo modificado para la produccion mejorada de alanina.
UY34377A (es) Proceso para producir peróxido de hidrógeno
MY183321A (en) Microorganism producing o-acetyl-homoserine and method for producing o-acetylhomoserine using the same
EA201590718A1 (ru) Способы получения макроциклических депсипептидов с использованием ацетальальдегида и новые промежуточные соединения
IN2014DN07958A (es)
MX2012010382A (es) Modulacion de acuaporinas con relaxina.
BR112013023144A2 (pt) método de tratamento de couro cabeludo
BR112013030164A2 (pt) pilha de combustível e processo de realização de uma pilha de combustível.